On a roll, Sage grabs a $575M deal on limited Asian rights to SAGE-217 — a potential gamechanger in depression
The data may be early and the patient population small, but in biotech today, who’s waiting for complete clarity?
On the day after …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
